Connect with us

Cannabis News

What Do New Ohio Restrictions On Marijuana And Hemp Mean For Consumers And Businesses?

Published

on

It is currently illegal to bring recreational cannabis products into Ohio, even if purchased legally in another state.

By Frank W. Lewis, Signal Cleveland

It was this story originally posted By Signal Cleveland. Sign up for their free newsletter at SignalCleveland.org/subscribe.

Intoxicating hemp products and THC-infused drinks are illegal again in Ohio and the maximum potency of the extracts is lower as a result The law entered into force on March 20.

Ohio voters legalized recreational marijuana and related products in 2023 when they passed Proposition 2. Republican lawmakers almost immediately vowed to roll back parts of it, and did so late last year, passing the new cuts mostly along party lines.

Here are some of the changes, including new criminal penalties for improperly transporting personal stash, bringing THC products across state lines or carrying them in public.

No more smoking or vaping in public places or businesses

You can attend a privately owned property if it’s not even a daycare center, halfway house, or community residential center.

Renters can still smoke in a house or apartment unless the lease prohibits it.

What are the new rules for storing edibles and weeds?

Edible and medical marijuana and other products should be stored in their original containers, even after opening.

What about driving with herbs, edibles or extracts?

If the original package has been opened, it should be stored in the trunk of your vehicle or behind the rear seats if there is no trunk. In other words, out of the driver’s hand.

The same rules apply to pipes, vape and other marijuana paraphernalia.

There are no out-of-state marijuana races or orders

It is currently illegal to bring recreational cannabis products into Ohio, even if purchased legally in another state. (Looking at you, Michigan.)

Sellers of these products, including edibles and grocers, cannot ship these products in Ohio.

Can I Door Dash or Uber Eats Marijuana?

Not right now. But the new law opens the door to home delivery of medical marijuana once the Cannabis Control Division drafts rules and standards.

Is it still legal to share marijuana with friends?

Yes, but with some changes.

  • The handover must be done in a private house or in an agricultural space.
  • The amount shared in one day cannot exceed 2 ½ ounces of plant material (excluding seeds and plants) or 15 grams of extract.
  • You still can’t take money for kindly sharing your eye.

Did they confuse it with power?

yes The THC level of the extracts is limited to 70 percent (below 90 percent).

The limit on medicinal and recreational plants remains at 35 percent.

Can I go to jail for using recreational cannabis products?

Yes, if it violates your employer’s policies.

That was true under Issue 2, the law passed by voters in 2023. But under the new law, workers fired for violating the drug policy are not eligible for state unemployment benefits.

I can still grow marijuana at home, right?

Home growing is still an option and the limit is six plants per adult over 21 or a total of 12 per home.

However, growing even one plant over that limit can lead to a charge of illegal marijuana cultivation, which can lead to criminal penalties.

No edibles in the form of gummy bears or fruit snacks

The new law outlaws the sale of marijuana products that resemble fictional characters, real people, animals, fruit, or images that may appeal to children.

Changing who gets tax revenue from the sale of marijuana

The new law eliminates the social equity and jobs fund created by No. 2 and money for substance abuse and addiction education and treatment programs.

Cities with dispensaries still receive 36% of tax revenue and the rest goes to the state’s general fund. Sales of recreational marijuana products in Ohio were $836 million last year.

For more information on all the latest changes, check out this side-by-side comparison table from Ohio State’s Moritz College of Law. Read the full set of legislative changes here.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Continue Reading

Cannabis News

Concert Series Specials launched for state medical cannabis patients

Published

on

By











Post Dispensary, Kentucky’s first medical cannabis dispensary, is connecting with patients in Owensboro, Henderson, Bowling Green, Elizabethtown, Madisonville, Hopkinsville and surrounding areas by aligning unique specials with the region’s summer concert calendar. Located at 300 N Main St. in Beaver Dam, minutes from major highways connecting these vibrant cities.

This summer, The Post Dispensary is offering special pricing and incentives for Concert Series Events at the Beaver Dam Amphitheater, SPARKS in the Park 4th of July celebration and surrounding events, such as Owensboro’s ROMP Festival (June 24-27, 2026). Patients can stop by before or after shows for big savings.

“We’re more than just a booty,” said a dispensary representative. “From Owensboro’s world-class ROMP Festival to Beaver Dam’s Amphitheater events, we’re making it convenient and budget-friendly for patients in Owensboro, Henderson, Bowling Green, Elizabethtown, Hartford and beyond to combine our love of music with compassionate care and an affordable product.”

The Post Dispensary hosts regular Patient Guidance events on the second Saturday of every month. These units have professionals on hand to assess patients and issue written certificates at low cost, application support and expert consultations in a welcoming environment. The next Patient Drive aligns perfectly with summer travel patterns, making it easy for patients from Owensboro, Bowling Green, Elizabethtown, Madisonville, Henderson, Madisonville and surrounding towns to plan a trip to Beaver Dam that combines care with community and entertainment.

For more information:
Post-Dispensary
thepostdispensary.com/










Continue Reading

Cannabis News

Missouri GOP Lawmakers Hope Trump’s Psychedelics Order Boosts Efforts To Allow Military Veteran Access In The State

Published

on

By

“Congratulations to President Trump for stepping up and taking the lead on this. PTSD is a killer among veterans.”

By Rebecca Rivas, Missouri Independent

Missouri state representative Dave Griffith has spent the past five years researching how psychedelic-assisted therapy has helped veterans struggling with post-traumatic stress disorder and depression.

His last legislative session in the House ended this May, and he pushed legislation for the last time allow clinical trials of psychedelic-assisted therapy in Missouri. In the final days of the session, the bill stalled in the Missouri Senate after passing the House with overwhelming support.

“I’m not going to be there next year, I’m term-limited,” said Griffith, a Republican who served as chairman of the House Veterans Affairs and Armed Services Committee. “It’s really about passing the torch to a lot of other veterans who are on the Veterans Commission and see the value in that.”

He was hopeful when he saw an announcement The US Department of Veterans Affairs announced last week a new clinical trial to evaluate the safety and effectiveness of methylenedioxymethamphetamine-assisted therapy.or MDMA-assisted therapy. MDMA is a synthetic substance made in a laboratory, according to the department, and is also called “ecstasy” or “molly” in recreational use.

“Congratulations to President Trump for stepping up and taking the lead on this,” said Griffith of Jefferson City. “PTSD is a killer among veterans. If you just listen to the testimony that’s been happening over the last five years in the Missouri House, the life-changing it’s been for them is a compelling reason why something like this works.”

A new trial follows Trump signed an executive order in April, “Expediting Medical Treatment for Serious Mental Illness.” The order aims to increase participation in clinical trials and accelerate innovative research models and drug approvals for psychedelics.

Directs the Secretary of Health and Human Services to allocate at least $50 million to support and collaborate with state governments that “have established or are developing programs to advance psychedelic drugs for serious mental illness.”

Without passing the legislation, Missouri will miss this opportunity, said Republican state representative Matthew Overcast of Ava.

Cloud hoped that Trump’s April order would help “grease the wheels” this year by state Rep. Richard West and state Rep. Richard West who sponsored the state to conduct a study on psilocybin and ibogaine therapy.

“The last couple of months there’s been a lot of feds on things that the states are reluctant to move forward with here,” Overcast said. “So it’s exciting.”

According to the VA’s announcement, the department is involved in 19 other active clinical trials focused on psychedelic therapies for mental health conditions that have received more than $23 million in outside funding.

The new trial, called “A Randomized Controlled Trial of MDMA-Assisted Therapy for PTSD and Alcohol Use Disorder in US Veterans,” will enroll about 80 veterans and compare outcomes between those receiving MDMA-assisted therapy and those receiving the same psychotherapy with an active placebo. VA is coordinating with the US Food and Drug Administration and plans to share trial data with FDA.

The trial will be conducted at the VA Providence Healthcare System, and will recruit veterans from the Providence, Rhode Island, campus in West Haven, Connecticut, and the VA Connecticut Healthcare System.

Trump’s executive order says there have been more than 6,000 veteran suicides per year for more than 20 years, and the current veteran suicide rate is twice that of the adult non-veteran population.

He says people with major depressive disorder and substance abuse disorder, among other serious mental illnesses, may relapse or fail to respond fully to standard medical and psychiatric therapies.

“Despite significant federal investment in research into potential advances in mental health care and treatment, our medical research system has yet to produce approved therapies that promote lasting improvements in the mental health status of the most complex patients,” the order states. “Innovative methods are needed to find long-term solutions for these Americans beyond existing prescription drugs.”

Missouri veterans John and Kara Grady, who own a hemp shop in Rosebud, strongly agree with the statement, they said. And they’d like to see Missouri’s veterans health system participate in clinical trials already underway.

“President Trump is opening up investigations for the veteran community,” said John Grady, “If you look at the numbers … we’ve lost more in the wars with mental health than we’ve lost.”

The lack of movement on psychedelic-assisted therapy legislation is among the reasons why John Grady is running for state representative over Bruce Sassmann in the state’s Republican primary.

“If you don’t agree with Trump on everything, at least he’s addressing this veteran issue right here,” Grady said. “Hopefully, we’ll be able to stop that number, we’ll stop that flow of our precious veterans dying by their own hands because they don’t have treatment.”

This story was first published by the Missouri Independent.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Continue Reading

Cannabis News

Germany’s medical cannabis imports post first quarterly decline since early 2024

Published

on

By

German imports of medical cannabis flowers fell to 50.5 tonnes in the first quarter of 2026, down from 60.8 tonnes in the previous quarter, the decline from the first quarter of 2024. According to a new EU and UK market update from Whitney Economics.

The drop lands against a year that went backwards. Germany took in more than 2025 tonnes of the product in 2025, more than double the 72,850 kilograms recorded in 2024, and import volumes have risen every year since 2018, when the figure remained below 4,500 kilograms. The first quarter number continues to match the high pace of 2025, which is why the report treats it as an early sign of stabilization rather than a turnaround.

Prices
The volume has not created a stable price. A gram of cannabis in a German pharmacy is approaching 4 euros, while a gram on the illegal market is around 8 euros, reversing the usual relationship between regulated and unregulated supply. The wholesale price is around 2 euros per gram, roughly half the retail price at the pharmacy. Pharmacy prices breached 3.99 euros in November 2025, and the report puts the overall compression close to 25% in two and a half years.

Germany legalized ownership in 2024 and restricted sales to pharmaceutical and telemedicine providers. Two access roads run parallel. Medical cannabis is mainly prescribed through private prescriptions, and recreational cannabis is available through membership of a cannabis association, with 400 licensed cultivation associations across the country, although the exact count varies by source. It is the medical segment that drives market growth, not the recreational segment.

Growth is based on telemedicine
Patients fill out an online questionnaire, receive a prescription from an affiliated physician, and in many cases have their order filled through an integrated pharmacy partner, with delivery within days and, in some cities, within hours. Between 600,000 and 700,000 self-employed consumers are supported by the telemedicine industry, compared to 200,000 to 300,000 medical patients supported by pharmacies. Total imports are now sufficient to supply between 900,000 and one million consumers.

© Philiprowe | Dreamstime

Market exposure
Critics argue that commercial interests risk overshadowing the medical nature of the system, and treatment does not always meet the required standard of control. Legislative initiatives that would tighten the framework are already on the table, including mandatory in-person inquiries and a ban on distribution of mail requests. The likely result of both measures is a significant decline in demand for medical cannabis flowers. Many telemedicine companies are preparing for the opportunity by building networks with local doctors and pharmacies.

Where patients and consumers would go if medical access is curtailed is an open question, as the recreational market lacks a real alternative for patients and cannabis clubs continue to face licensing hurdles at the state level.

Part of the difficulty in reading the market is that import figures say less than they seem. More cannabis is entering the country than ever before, but how much is reaching consumers and what the actual demand is is unclear. Without a nationwide data framework, the market functions as a black box, and excess supply and actual demand are difficult to measure with great precision. Supply has tended to expand faster than the market can absorb, with no forecast to confirm mature demand, and prices have adjusted downward as a result.

Germany has had a signal effect across Europe since the start of its reform, although its model has drawn criticism, with the mixing of medical and recreational consumption a recurring complaint. Countries that have traditionally taken a conservative line, France among them, have gone to a more formalized medical field, under stricter conditions and without adopting the medical flower like Germany.

For more information:
Whitney Economics
Beau Whitney
(503) 724-3084
www.whitneyeconomics.com

Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media